Predicting Power, Protecting Patients: AI-Driven Battery Intelligence for Medical Devices In Healthcare, a dead battery isn’t just an inconvenience – it’s a clinical threat. From
Zero Risks with AI-Powered Document Intelligence Solution When a large tech company was losing time and money chasing contracts across SharePoint, AROBS produced a game-changer:
AI-Driven Precision in Syringe Filling for Pharma and Laboratory Applications According to Data Bridge Market Research, the global medical automation market is valued at
Transformation of a 20+ years old legacy system for clinical trials ethics approvals A globally recognized pharmaceutical company was struggling with a legacy system, over
Global Clinical Safety Management System Industry Context & Pain Points: Drug safety and pharmacovigilance are under growing global scrutiny, driving demand for advanced IT solutions
Success Story: Clinical Trial Management Solution Validation & Market Expansion “The life sciences sector is poised for a dynamic year in 2025, with significant developments
Critical Data Migration in Pharma M&A (Ensuring Trial Continuity) Industry Context: The pharmaceutical sector is experiencing a surge in strategic mergers and acquisitions (M&A) deals
AROBS accelerates international expansion and invests in emerging technologies, with EBITDA growth in H1 2025 Cluj-Napoca, August 27, 2025 – AROBS Transilvania Software (BVB: AROBS),
AROBS Systems contributes to the digital transformation of the Romanian National Employment Agency (ANOFM) through a strategic project financed via the PNRR Cluj-Napoca, 26 August
JobCloud and AROBS: A Partnership Built on Growth and Innovation Building reliable software solutions means more than delivering code. It means creating teams that understand
Long gone are the times when the Sun and the stars used to guide vessels in their quest on the oceans and the seas, right?
Smart Finance 2025: Architecting the Future of Financial Intelligence Finance has become an engine of strategy, expanding its power beyond its administrative appearance. In 2025,